Clinical Trials Directory

Trials / Sponsors / HRYZ Biotech Co.

HRYZ Biotech Co.

Industry · 8 registered clinical trials — 2 currently recruiting.

StatusTrialPhaseStarted
RecruitingMASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Leiomyosarcoma, Liposarcoma, Synovial Sarcoma
Phase 22024-02-21
RecruitingHRYZ-T101 Injection for HPV18 Positive Solid Tumor
Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina
Phase 12023-11-01
UnknownHRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer
Phase 12023-03-21
CompletedMASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.
Solid Tumors
Phase 12020-04-21
UnknownMASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma
Sarcoma
EARLY_Phase 12019-11-22
UnknownA Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor
Advanced Gastric Cancer
Phase 12018-04-19
TerminatedA Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tum
Advanced Solid Tumors
Phase 12017-02-22
SuspendedMultiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resect
Hepatocellular Carcinoma
Phase 1 / Phase 22013-07-01